Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

In Situ Vaccination of Tumors Using Plant Viral Nanoparticles.

Murray AA, Sheen MR, Veliz FA, Fiering SN, Steinmetz NF.

Methods Mol Biol. 2019;2000:111-124. doi: 10.1007/978-1-4939-9516-5_10.

PMID:
31148013
2.

In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.

Sheen MR, Fiering S.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2019 Jan;11(1):e1524. doi: 10.1002/wnan.1524. Epub 2018 Apr 18. Review.

PMID:
29667346
3.

Combination of Plant Virus Nanoparticle-Based in Situ Vaccination with Chemotherapy Potentiates Antitumor Response.

Lee KL, Murray AA, Le DHT, Sheen MR, Shukla S, Commandeur U, Fiering S, Steinmetz NF.

Nano Lett. 2017 Jul 12;17(7):4019-4028. doi: 10.1021/acs.nanolett.7b00107. Epub 2017 Jun 26.

4.

Exploiting Uptake of Nanoparticles by Phagocytes for Cancer Treatment.

Sheen MR, Fiering S.

Methods Mol Biol. 2017;1530:355-367. doi: 10.1007/978-1-4939-6646-2_22.

PMID:
28150214
5.

Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer.

Sheen MR, Marotti JD, Allegrezza MJ, Rutkowski M, Conejo-Garcia JR, Fiering S.

Oncogenesis. 2016 Oct 31;5(10):e267. doi: 10.1038/oncsis.2016.65.

6.

Myristoylated p110α Causes Embryonic Death Due to Developmental and Vascular Defects.

Sheen MR, Warner SL, Fields JL, Conejo-Garcia JR, Fiering S.

Open Life Sci. 2015 Oct;10(1):461-478. Epub 2015 Oct 19.

7.

IL15 Agonists Overcome the Immunosuppressive Effects of MEK Inhibitors.

Allegrezza MJ, Rutkowski MR, Stephen TL, Svoronos N, Tesone AJ, Perales-Puchalt A, Nguyen JM, Sarmin F, Sheen MR, Jeng EK, Tchou J, Wong HC, Fiering SN, Conejo-Garcia JR.

Cancer Res. 2016 May 1;76(9):2561-72. doi: 10.1158/0008-5472.CAN-15-2808. Epub 2016 Mar 15.

8.

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer.

Lizotte PH, Wen AM, Sheen MR, Fields J, Rojanasopondist P, Steinmetz NF, Fiering S.

Nat Nanotechnol. 2016 Mar;11(3):295-303. doi: 10.1038/nnano.2015.292. Epub 2015 Dec 21.

9.

Stimulating antitumor immunity with nanoparticles.

Sheen MR, Lizotte PH, Toraya-Brown S, Fiering S.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2014 Sep-Oct;6(5):496-505. doi: 10.1002/wnan.1274. Epub 2014 May 21. Review.

10.

Local hyperthermia treatment of tumors induces CD8(+) T cell-mediated resistance against distal and secondary tumors.

Toraya-Brown S, Sheen MR, Zhang P, Chen L, Baird JR, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S.

Nanomedicine. 2014 Aug;10(6):1273-1285. doi: 10.1016/j.nano.2014.01.011. Epub 2014 Feb 22.

11.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

12.

Phagocytes mediate targeting of iron oxide nanoparticles to tumors for cancer therapy.

Toraya-Brown S, Sheen MR, Baird JR, Barry S, Demidenko E, Turk MJ, Hoopes PJ, Conejo-Garcia JR, Fiering S.

Integr Biol (Camb). 2013 Jan;5(1):159-71. doi: 10.1039/c2ib20180a.

13.

Frameshift mutation in p53 regulator RPL26 is associated with multiple physical abnormalities and a specific pre-ribosomal RNA processing defect in diamond-blackfan anemia.

Gazda HT, Preti M, Sheen MR, O'Donohue MF, Vlachos A, Davies SM, Kattamis A, Doherty L, Landowski M, Buros C, Ghazvinian R, Sieff CA, Newburger PE, Niewiadomska E, Matysiak M, Glader B, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH.

Hum Mutat. 2012 Jul;33(7):1037-44. doi: 10.1002/humu.22081. Epub 2012 Apr 16.

14.

The ribosomal basis of Diamond-Blackfan Anemia: mutation and database update.

Boria I, Garelli E, Gazda HT, Aspesi A, Quarello P, Pavesi E, Ferrante D, Meerpohl JJ, Kartal M, Da Costa L, Proust A, Leblanc T, Simansour M, Dahl N, Fröjmark AS, Pospisilova D, Cmejla R, Beggs AH, Sheen MR, Landowski M, Buros CM, Clinton CM, Dobson LJ, Vlachos A, Atsidaftos E, Lipton JM, Ellis SR, Ramenghi U, Dianzani I.

Hum Mutat. 2010 Dec;31(12):1269-79. doi: 10.1002/humu.21383.

15.

Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia.

Doherty L, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Clinton C, Schneider HE, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Glader B, Arceci RJ, Farrar JE, Atsidaftos E, Lipton JM, Gleizes PE, Gazda HT.

Am J Hum Genet. 2010 Feb 12;86(2):222-8. doi: 10.1016/j.ajhg.2009.12.015. Epub 2010 Jan 28. Erratum in: Am J Hum Genet. 2010 Apr 9;86(4):655.

16.

Ribosomal protein L5 and L11 mutations are associated with cleft palate and abnormal thumbs in Diamond-Blackfan anemia patients.

Gazda HT, Sheen MR, Vlachos A, Choesmel V, O'Donohue MF, Schneider H, Darras N, Hasman C, Sieff CA, Newburger PE, Ball SE, Niewiadomska E, Matysiak M, Zaucha JM, Glader B, Niemeyer C, Meerpohl JJ, Atsidaftos E, Lipton JM, Gleizes PE, Beggs AH.

Am J Hum Genet. 2008 Dec;83(6):769-80. doi: 10.1016/j.ajhg.2008.11.004.

17.

Interstitial tonicity controls TonEBP expression in the renal medulla.

Sheen MR, Kim JA, Lim SW, Jung JY, Han KH, Jeon US, Park SH, Kim J, Kwon HM.

Kidney Int. 2009 Mar;75(5):518-25. doi: 10.1038/ki.2008.601. Epub 2008 Dec 3.

18.

Hypertonicity stimulates PGE2 signaling in the renal medulla by promoting EP3 and EP4 receptor expression.

Kim JA, Sheen MR, Lee SD, Jung JY, Kwon HM.

Kidney Int. 2009 Feb;75(3):278-84. doi: 10.1038/ki.2008.498. Epub 2008 Oct 8.

19.

Downregulation of renal TonEBP in hypokalemic rats.

Jeon US, Han KH, Park SH, Lee SD, Sheen MR, Jung JY, Kim WY, Sands JM, Kim J, Kwon HM.

Am J Physiol Renal Physiol. 2007 Jul;293(1):F408-15. Epub 2007 Apr 4.

20.

Downregulation of renal sodium transporters and tonicity-responsive enhancer binding protein by long-term treatment with cyclosporin A.

Lim SW, Ahn KO, Sheen MR, Jeon US, Kim J, Yang CW, Kwon HM.

J Am Soc Nephrol. 2007 Feb;18(2):421-9. Epub 2007 Jan 3.

21.

Comparison of experimental lung injury from acute renal failure with injury due to sepsis.

Kim DJ, Park SH, Sheen MR, Jeon US, Kim SW, Koh ES, Woo SK.

Respiration. 2006;73(6):815-24. Epub 2006 Sep 5.

PMID:
16960438
22.

Mre11-Rad50-Nbs1 complex is activated by hypertonicity.

Sheen MR, Kim SW, Jung JY, Ahn JY, Rhee JG, Kwon HM, Woo SK.

Am J Physiol Renal Physiol. 2006 Nov;291(5):F1014-20. Epub 2006 Jun 20.

23.

How tonicity regulates genes: story of TonEBP transcriptional activator.

Jeon US, Kim JA, Sheen MR, Kwon HM.

Acta Physiol (Oxf). 2006 May-Jun;187(1-2):241-7. Review.

PMID:
16734761
24.

TonEBP is inhibited by RNA helicase A via interaction involving the E'F loop.

Colla E, Lee SD, Sheen MR, Woo SK, Kwon HM.

Biochem J. 2006 Jan 1;393(Pt 1):411-9.

25.

Structure of human PRL-3, the phosphatase associated with cancer metastasis.

Kim KA, Song JS, Jee J, Sheen MR, Lee C, Lee TG, Ro S, Cho JM, Lee W, Yamazaki T, Jeon YH, Cheong C.

FEBS Lett. 2004 May 7;565(1-3):181-7.

26.

Multiple domains of TonEBP cooperate to stimulate transcription in response to hypertonicity.

Lee SD, Colla E, Sheen MR, Na KY, Kwon HM.

J Biol Chem. 2003 Nov 28;278(48):47571-7. Epub 2003 Sep 11.

27.

Congenital longitudinal deficiency of the tibia.

Schoenecker PL, Capelli AM, Millar EA, Sheen MR, Haher T, Aiona MD, Meyer LC.

J Bone Joint Surg Am. 1989 Feb;71(2):278-87.

PMID:
2918013
28.

The interaction of the nucleoside analogues, formycins A and B, with xanthine oxidase and hepatic aldehyde oxidase.

Sheen MR, Martin HF, Parks RE Jr.

Mol Pharmacol. 1970 May;6(3):255-65. No abstract available.

PMID:
5443531

Supplemental Content

Loading ...
Support Center